#United States #New York #Class Action #Levi & Korsinsky #UroGen Pharma

Legal Notice for UroGen Pharma Shareholders

If you are an investor in UroGen Pharma Ltd. (NASDAQ: URGN) and have witnessed monetary losses, you may be eligible to participate in an ongoing class action lawsuit led by the law firm Levi & Korsinsky, LLP. This lawsuit aims to hold the company accountable for alleged securities fraud that has impacted shareholders significantly.

Key Information Regarding the Lawsuit

The class action lawsuit is focused on a time frame between July 27, 2023, and May 15, 2025. Allegations suggest that UroGen Pharma made misleading statements and failed to disclose critical information regarding the effectiveness of their lead drug candidate, UGN-102. One significant claim states that the clinical study used for this drug lacked a proper control group, raising concerns about its reliability.

Moreover, regulatory guidance from the FDA appeared to be ignored, putting the potential approval of UGN-102 at risk. If these claims are proven, UroGen’s positive assertions about its business prospects, operations, and the viability of its product pipeline may be considered materially misleading.

How to Participate in the Class Action

Affected shareholders have until July 28, 2025, to request to be designated as lead plaintiffs, which is not a requirement for receiving any potential compensation. Even without this designation, shareholders can still partake in potential recoveries.

There are no upfront fees for those who qualify as class members, which means they can seek compensation for their losses without any out-of-pocket expenses. This could be a critical opportunity for investors who have suffered due to the alleged mismanagement and misinformation presented by the company.

Why Levi & Korsinsky?

Levi & Korsinsky has built a reputable history over the last two decades, securing hundreds of millions of dollars for aggrieved shareholders. The firm has been recognized consistently as one of the top securities litigation firms in the United States. Mr. Joseph E. Levi and his team are currently handling the proceedings and are available for consultations regarding potential claims.

Contact Information

For further information or to submit your claim, you can contact:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

This opportunity presents a significant avenue for investors to seek justice following substantial losses attributed to potentially fraudulent activities. Don't miss the chance to see if you qualify for this class action.